Skip to content
Medical Health Aged Care

World-first tool to predict risk of sudden cardiac arrest

Victor Chang Cardiac Research Institute 2 mins read

 

Scientists at the Victor Chang Cardiac Research Institute have developed a world-first individualised risk prediction tool for people suffering from a type of heart arrhythmia that can cause sudden cardiac arrest.

This is the first time a gene mutation-specific test has been applied to predict the severity of heart disease.

The discovery was made in conjunction with colleagues at the Vanderbilt University Medical Centre and could also benefit patients suffering from other heart arrhythmias and neurological conditions.

Lead author Professor Jamie Vandenberg, Deputy Director of the Victor Chang Cardiac Research Institute, says the findings published in Circulation would enable patients with one of the most common inherited heart diseases - Long QT syndrome - to discover how severe their condition was.

Professor Vandenberg says: "Genetic testing for inherited heart diseases has been transformative, but there have been limitations in what it can tell you. It might reveal you have the disease, but there has been no way of using this genetic information to determine how high your risk is for suffering a sudden cardiac arrest.

"This will provide patients and their families with answers and better enable clinicians to tailor treatment appropriately."

Long QT Syndrome is a heart rhythm disorder that can cause sudden cardiac death and generally affects people who are otherwise fit and healthy. Around one in 2000 Australians will have this condition.

The researchers investigated 533 genetic variants or mutations associated with Long QT syndrome from 1458 patients. The mutations affect the function of ion channel gene variants.

They analysed every mutation and its function using a high-speed electrical test, a high-throughput automated patch clamp assay.

They revealed which genetic mutations were the most dangerous by comparing these findings against traditional testing methods and using patient records.

They discovered that some genetic mutations reduced the function of the ion channel by up to 90 percent, resulting in a 13.3-fold greater risk of major cardiac events (arrhythmia, sudden death). A 75 percent reduction in function was associated with an 8.6-fold greater risk of major cardiac events.

Fellow author Dr Chai-Ann Ng of the Victor Chang Cardiac Research Institute says: "We have shown that not every diagnosis of Long QT is equal, and the risk of having a sudden cardiac arrest can vary dramatically depending on the exact genetic mutation.

“Our findings will make a huge difference in how these high-risk patients are cared for in the future. We are also actively working on adapting this test to patients affected by other heart arrhythmias and neurological conditions."

Contact details:

Julia Timms j.timms@victorchang.edu.au 0457517355

Media

More from this category

  • Disability, Medical Health Aged Care
  • 20/12/2024
  • 17:36
Kuremara

Kuremara to Open a State-of-the-Art Activity Center in Milton, QLD, in January 2025

Kuremara, a trusted and leading NDIS-registered provider in Australia, is excited to announce the opening of its newest facility—a cutting-edge activity center in Milton,…

  • Contains:
  • Legal, Medical Health Aged Care
  • 20/12/2024
  • 17:29
JGA Saddler

BREAKING NEWS: Australian law firm takes on Johnson & Johnson for selling Australians ineffective medicine

Vision available: Lawyer and doctor VNR, editorial photos and radio grabs included can be found in this SharePoint File In-person lawyer interviews available by…

  • Contains:
  • Medical Health Aged Care
  • 20/12/2024
  • 12:01
NDARC/UNSW

ADHD drug shows promise for treating methamphetamine dependence, landmark Australian study shows

A prescription medication used to treat attention deficit hyperactivity disorder (ADHD) could be repurposed as the first pharmacotherapy for people with methamphetamine dependence, according to a study published in Addiction. Results from the landmark ‘LiMA’ trial show that thepsychostimulant lisdexamfetamine can drastically reduce the need to use methamphetamine among those who are dependent on the illicit drug. Lead author and addiction medicine specialist Professor Nadine Ezard, who is Director of the National Centre for Clinical Research on Emerging Drugs (NCCRED), said the results were promising. "There is currently no pharmacotherapy approved for treating methamphetamine dependence," Professor Ezard said. “While further…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.